Adenoviral vectors: development and application

Bibliography

• HORWITZ MS: Adenoviridae and their replication. In: •Fundamental Virology (2nd Edition). Field BN, Knipe DM, Chanock RM et al. (Ed.), Raven Press, New York (1990) 771–813. An important chapter on adenoviral replication.
   Google Scholar
• SUSSENBACH JS: The structure of the genome. In: The Adenoviruses. Ginsberg HS (Ed.), Plenum Publishing Corp., New York (1984):35–124.
   Google Scholar
• PHILIPSON L: Adenovirus assembly. In: The Adenoviruses. Ginsberg HS (Ed.), Plenum Publishing Corp., New York (1984) 309–337.
   Google Scholar
• STRATFORD-PERRICAUDET L, PERRICAUDET M: Gene •transfer into animals: the promise of adenovirus. In: Human Gene Transfer. Cohen-Haguenauer O, Boiron M (Eds.), Editions John Libbey Eurotext, France (1991):51–61. An early review describing the potential and development of Ad vectors. GRAHAM FL, PREVEC L: Manipulation of adenovirus vectors. In: Methods in Molecular Biology (Vol. 7), Gene Transfer and Expression Protocols. Murray EJ (Ed.), The Humana Press, Inc., Clifton, NJ (1990:109–128. An excellent chapter describing the basic techniques for developing Ad vectors.
   Google Scholar
• NEVINS JR: Transcriptional activation by the adenovirus ElA proteins. Semin. Vim]. (1993) 4:25–31.
   Google Scholar
• PETTERSSON U, ROBERTS RJ: Adenovirus gene expres- •sion and replication: a historical review. In: Cancer Cells (Vol. 4): DNA Tumour Viruses. Botchan M, Glodzicker T, Sharp PA (Eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1986):37–57. A systematic review covering early studies of adenovirology.
   Google Scholar
• WOLD WSM, GOODING LR: Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology (1991) 184:1–8.
   PubMed Web of Science ®Google Scholar
• HALBERT DN, CUTT JR, SHENK T: Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J. Vim]. (1985) 56:250–257.
   Web of Science ®Google Scholar
• SHAW AR, ZIFF EB: Transcriptions from the adenovirus-2 major later promoter yield a single early family of 3' coterminal mRNA and five late families. Cell (1980) 22:905–916.
   PubMed Web of Science ®Google Scholar
• STRAUS SE: Adenovirus infections in humans. In: The Adenoviruses. Ginsberg HS (Ed.), New York, Plenum Press (1984):451–496.
   Google Scholar
• HUANG S, ENDO RI, NEMEROW: Upregulation of inte-grins avI33 and avI35 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene de-livery. J. Vim]. (1995) 69:2257–2263.
   Web of Science ®Google Scholar
• PHILIPSON L, LONDERG-HOLM K, PETTERSSON U: Virus- •receptor interaction in an adenovirus system. J. Vim]. (1968) 2:1064-1075. An early study of Ad-receptor interactions.
   Google Scholar
• DEFER C, BELIN MT, CAILLET-BOUDIN ML et al.: Human adenovirus-host cell interactions: comparative study with members of subgroups B and C. J. Virol (1990) 64:3661–3673.
   PubMed Web of Science ®Google Scholar
• BERGELSON JM, CUNNINGHAM JA, DROGUETT G et al.:
   Google Scholar
• Isolation of a common receptor for coxsackie B virusesand adenoviruses 2 and 5. Science (1997) 275:1320-1323. The first publication describing the Ad fibre receptor.
   Google Scholar
• DALES S, CHARDONNET Y: Early events in the interac-tion of adenoviruses with HeLa cells: association with microtubules and the nuclear pore complex during vectorial movement of the inoculum. Virology (1973) 56:465–483.
   PubMed Web of Science ®Google Scholar
• WICKHAM TJ, MATHIAS P, CHERESH DA et al.: Integrins •(435 and ocl35 promote adenovirus internalisation but not virus attachment. Cell (1993) 73:309-319. An experimental study on the pentone base receptor.
   Google Scholar
• BAI M, HARFE B, FREIMUTH P: Mutations that alter an Arg-Gly-Asp MGM sequence in adenovirus type 2 pen-tone base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J. Virol. (1993) 67:5198–5205.
   PubMed Web of Science ®Google Scholar
• FITZGERALD DJP, TROWBRIDGE JS. PASTAN I et al.: En-hancement of toxicity of antitransferrin receptor anti-body-pseudomonas exotoxin conjugates by adenovirus. Proc. Natl. Acad. Sci. USA (1983) 80:4134–4138.
   Google Scholar
• FITZGERALD DJP, PADMANABHAN R, PASTAN I et al.: Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell (1983) 32:607–617.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA K, ROSEN FELD MA, SETH P et al.: Ade-novirus-mediated augmentation of cell transfection with unmodified plasmid vectors. J. Biol. Chem. (1993) 268:2300–2303.
   PubMed Web of Science ®Google Scholar
• SETH PJ: Adenovirus-dependent release of choline fromplasma membrane vesicles at an acidic pH is mediated by the pentone base protein. Virology (1994) 68:1204–1206.
   Web of Science ®Google Scholar
• WOHLFART C: Neutralisation of Adenoviruses: kinetics,stoichiometry, and mechanisms. J. Vim]. (1988) 62:2321–2328.
   Web of Science ®Google Scholar
• GREBER UF, WILLETTS M, WEBSTER P et al.: Stepwise •dismantling of Adenovirus 2 during entry into cells. Cell (1993) 75:477-486. An experimental study on the entty of Ad into cells.
   Google Scholar
• GREEN M, DAESCH GE: Biochemical studies on adenovirus multiplication. I. Kinetics of nucleic acid and protein synthesis in suspension cultures. Virology (1961) 13:169–176.
   Google Scholar
• KELLY TJ, Jr.: Adenovirus DNA replication. In: The Ade-noviruses. Ginsberg HS (Ed.), New York, Plenum Press (1984)271–308.
   Google Scholar
• LECHNER RL, KELLY TJ, Jr.: The structure of replicating •adenovirus 2 DNA molecules. Cell (1977) 12:1007-1020. An early study of the Ad DNA replication mechanism.
   Google Scholar
• REKOSH DMK, RUSSELL WC, BELLET AJD et al: Identification of a protein linked to the ends of adenovirus DNA. Cell (1977) 11:283–295.
   PubMed Web of Science ®Google Scholar
• GUGGENHEIMER RA, NAGATA K, FIELD J et al.: In vitro synthesis of full length adenoviral DNA. In: UCLA sympo-sia on mechanisms of DMA replication and recombination. Cozzarelli N, Alan R Liss (Eds.), New York, (1983):395–421.
   Google Scholar
• PRUIJN GJ, VAN DRIEL W, VAN DER VLIET PC: Nuclear Factor III, a novel sequence-specific DNA binding pro-tein from HeLa cells stimulating adenovirus DNA repli-cation. Nature (1986) 322:656–659.
   PubMed Web of Science ®Google Scholar
• HAMMARSKJOELD M-L, WINBERG G: Encapsidation of •adenovirus 16 DNA is directed by a small DNA sequence at the left end of the genome. Cell (1980) 20:787-795. An early study of the packaging mechanism of Ad.
   Google Scholar
• ROBBINSON CC, TIBBETTS C: Polar encapsidation of adenovirus DNA: evolutionary variants reveal dispen-sable sequences near the left ends of AdV3 genomes. Virology (1984) 137:276–286.
   PubMed Web of Science ®Google Scholar
• HEARING P, SAMULSI RJ, WISHART WL et al: Identification of a repeated sequence element required for efficientencapsidation of the adenovirus type 5 genome. J. Vim]. (1987) 671:2555-2558. The first report on Ad5 packaging sequences.
   Google Scholar
• GRABLE M, HEARING P: Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. J. Virol. (1990) 64:2047–2056.
   PubMed Web of Science ®Google Scholar
• GRABLE M, HEARING P: Cis and trans requirements for the selective packaging of adenovirus type 5 DNA. J Vim]. (1992) 6:723–731.
   Google Scholar
• SCHMID SI, HEARING P: Bipartite structure and func- •tional independence of adenovirus type 5 packaging elements. J. Vim]. (1997) 71:3375-3384. An experimental study on the Ad5 packaging sequences.
   Google Scholar
• GRAHAM FL, SMILEY J, RUSSELL WC et al: Characteristics of a human cell line transformed by DNA from humanadenovirus type 5. J. Gen. Vim] (1977) 36:59-72. The first report of the construction of an Ad helper cell line.
   Google Scholar
• STOW ND: Cloning of a DNA fragment from the left- •hand terminus of the adenovirus type 2 genome and its use in site-directed mutagenesis. j Virol. (1981) 37:171-180. An early paper on the technical development of Ad vectors.
   Google Scholar
• CHINNADURAI G, CHINNADURAI S, BRUSSA J: Physical mapping of a large-plaque mutation of adenovirus type 2. J. Virol (1979) 32:623–628.
   PubMed Web of Science ®Google Scholar
• BERKNER KL, SHARP PA: Generation of adenovirus by transfection of plasmids. Nucleic Acids Res. (1983) 17:6003–6021.
   Google Scholar
• GRAHAM FL: Covalently closed circles of human ade- •novirus DNA. EMBO J (1984) 3:2917-2922. A study outlining the use of plasmid co-transfection for the genera-tion of Ad through homologous recombination.
   Google Scholar
• MCGRORY WJ, BAUTISTA DS, GRAHAM FL: A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology (1988) 163:614–617.
   PubMed Web of Science ®Google Scholar
• BETT AJ, HADDARA W, PREVEC L et al.: An efficient and •flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. NatI Acad. Sci. USA (1994) 91:8802-8806. An interesting paper describing plasmid recombination technology for Ad vector.
   Google Scholar
• KETNER G, SPENCER F, TUGENDREICH S et al.: Efficient •manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone. Proc. Natl. Acad. Sci. USA (1994) 91:6186-6190. A new method for the recombination Ad generation.
   Google Scholar
• CHARTIER C, DEGRYSE E, GANTZER M et al.: Efficient generation of recombinant adenovirus vectors by ho-mologous recombination in Escherichia coil. J. Vim]. (1996) 70:4805–4810.
   Web of Science ®Google Scholar
• CROUZET J, NAUDIN L, ORSINI C et al: Recombinational •construction in Escherichia coli of infectious adenovi-ral genomes. Proc. Natl. Acad. Sci. USA (1997) 94:1414-1419. A new method for recombinant Ad generation.
   Google Scholar
• HARDY S, KITAMURA M, HARRIS-STANSIL T et al.: Con- •struction of adenovirus vectors through cre4oxrecom-bination. j Vim]. (1997) 71:1842-1849. A new method for recombinant Ad generation.
   Google Scholar
• MIYAKE S, MAKIMURU M, KANAGAE Y et al.: Efficient •generation of recombinant adenoviruses using ade-novirus DNA-terminal protein complex and a cosmid bearing the full-length virus gene. Proc. Natl. Acad. Sci. USA (1996) 93:1320-1324. A new method for recombinant Ad generation.
   Google Scholar
• GREEN M, WOLD WSM: Human adenoviruses: growth,
   Google Scholar
• purification, and transfection assay. In: Methods & Enzy-mology Volume LVIII Academic Press Inc. (1979):425–435. An early methodology paper for Ad vectors.
   Google Scholar
• GRAHAM FL: Growth of 293 cells in suspension culture. J. Gem. Vim]. (1987) 68:937–940.
   PubMed Web of Science ®Google Scholar
• GREEN M, PINA M Biochemical studies on adenovirusmultiplication, VI. Properties of highly purified tumorigenic human adenoviruses and their DNA's. Proc. Natl. Acad. Sci. USA (1964) 51:1251–1259.
   PubMed Web of Science ®Google Scholar
• HUYGHE BG, LIU X, SUTJIPTO S et al.: Purification of type •5 recombinant adenovirus encoding human p53 by column chromatography. Human Gene Ther. (1995) 6:1403-1416. A method paper reporting Ad vector purification using column chromatography.
   Google Scholar
• ROSENFELD MA, YOSHIMURA K, TRAPNELL BC et al.: In vivo transfer of the human cystic fibrosis transmem-brane conductance regulator gene to the airway epithe-lium. Cell (1992) 68:143-155. An early study of Ad-mediated gene transfer for hereditary diseases in animal model.
   Google Scholar
• PINTERIC L, TAYLOR J: The lowered drop method for the preparation of specimens of partially purified virus lysates for quantitative electron micrographic analysis. Virology (1962) 18:359–371.
   Web of Science ®Google Scholar
• LAWRENCE WC, GINSBERG H: Intracellular uncoating of type 5 adenovirus deoxyribonucleic acid. J. Virol (1967) 1:851–867.
   PubMedGoogle Scholar
• MITTEREDER N, MARCH KL, TRAPNELL BC: Evaluation of the concentration and bioactivity of adenovirus vectorsfor gene therapy. J. Virol (1996) 70:7498-7509. A well-designed study evaluating the concentration and bioactivity of Ad vectors.
   Google Scholar
• ZHANG W-W, FANG X, MAZUR W et al.: High-efficiency •gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. (1994) 1:5-13. An early study of Ad-mediated tumour suppressor gene therapy for cancer.
   Google Scholar
• ZHANG W-W, ALEMANY R, WANG J et al.: Safety evalu-ation of AdV5CMV-p53 in vitro and in viva Human Gene Ther. (1995) 6:155-164.
   Google Scholar
• ZHANG W-W, KOCH P, ROTH JA: Detection of wild-type •contamination in recombinant adenoviral preparation by PCR. BioTechniques (1995) 18:444-447. A report outlining developments in methodology.
   Google Scholar
• ZHANG W-W: Adenovirus as a system for delivering and expressing tumor suppressor genes in tumor cells. Methods (1995) 8:198-214. A comprehensive report on preclinical assay methods for Ad vectors.
   Google Scholar
• SHABRAM PW, GIROUX DD, GOUDREAU AM et al: Ana-lytical anion-exchange HPLC of recombinant type 5 adenoviral particles. Human Gene Ther. (1997) 8:453–465.
   PubMed Web of Science ®Google Scholar
• BOUCHER RC, KNOWLES MR: Gene therapy for cystic fibrosis using El-deleted adenovirus: a phase I trial in the nasal cavity. Human Gene Ther. (1994) 5:615–639.
   PubMed Web of Science ®Google Scholar
• LOCHMULLER A, JANI J, HUARD S et al.: Emergence of early region 1-containing replication-competent ade-novirus in stocks of replication-defective adenovirus recombinants (E1+E3) during multiple passages in 293 cells. Human Gene Ther. (1994) 5:1485–1491.
   PubMed Web of Science ®Google Scholar
• SMITH CD, CRAFT DW, SHIROMOT RS et aL: Alternativecell line for virus isolation. J. Clin. MicrobioL (1986) 24:265–268.
   PubMed Web of Science ®Google Scholar
• RABSON AS, O'CONNOR CT, BEREZESKY IK et al.: En-hancement of adenovirus growth in African green monkey kidney cell cultures by SV40. Proc. Soc. Exp. Biol. Med. (1964) 116:187–190.
   Google Scholar
• HEUBNER RJ, CHANOCK RM, RUBIN BA et al.: Inductionby adenovirus type 7 of tumors in hamsters having the antigenic characteristics of SV40 virus. Proc. Natl. Acad. Sci. USA (1964) 52:1333–1340.
   PubMed Web of Science ®Google Scholar
• LEWIS AM, Jr., BAUM SG, PRIGGE KO et al: Occurrence of adenovirus SV40 hybrids among monkey kidney cell adapted strains of adenovirus. Proc. Soc. Exp. Biol. Med. (1966) 122:214–218.
   PubMed Web of Science ®Google Scholar
• RAPP F, MELNICK JL, BUTEL JS et al: The incorporation of SV40 genetic material into adenovirus 7 as measured by intranuclear synthesis of SV40 tumor antigen. Proc. Natl. Acad. Sci. USA (1964) 52:1348–1352.
   PubMed Web of Science ®Google Scholar
• GRODZICKER T, SAMBROOK J: Adenovirus-SV40 hy-brids: a model system for expression of foreign se-quences in an animal virus vector. In: Genetic Engineering, Principles and Methods. Setlow JK, Hollaender A (Eds.), Plenum Press, New York (1979):103–114.
   Google Scholar
• TOOZE J: Adenovirus-SV40 hybrids. In: Molecular biology •of DNA tumour viruses (2nd edition). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982):577–614. A comprehensive review on Ad-5V40-hybrids.
   Google Scholar
• BERKNER KL, SHARP PA: Expression of dihydrofolate reductase and of the adjacent Elb region in an AdV5-di-hydrofolate reductase recombinant virus. Nucleic Adds Res (1984) 12: 1925-1941.
   Google Scholar
• BERKNER KL, SCHAFFHAUSEN BS, ROBERTS TM et al.: Abundant expression of polyomavirus middle T anti-gen and dihydrofolate reductase in an adenovirus re-combinant. J. ViroL (1987) 61:1213–1220.
   PubMed Web of Science ®Google Scholar
• DAVIDSON D, HASSEL JA: Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector. J. ViroL (1987) 61:1226–1239.
   PubMed Web of Science ®Google Scholar
• LOGAN J, SHENK T: Adenovirus tripartite leader se-quence enhances translation of RNAs later after infec-tion. Proc. Natl. Acad. Sci. USA (1984) 81:3655–3659.
   PubMed Web of Science ®Google Scholar
• BERKNER KL, SHARP PA: Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant. Nucleic Acids Res (1985) 13:841–857.
   PubMed Web of Science ®Google Scholar
• DAVIS AR, KOSTEK B, MASON et al.: Expression of hepa-titis B surface antigen with a recombinant adenovirus. Proc. Natl. Acad. Sci. USA (1985) 82:7560–7564.
   PubMed Web of Science ®Google Scholar
• MANSOUR SL, GRODZICKER T, TJAN R: Downstream sequences affect transcription initiation from the ade-novirus major late promoter. Md. Cell Biol. (1986) 6:2684–2694.
   Web of Science ®Google Scholar
• SOLNICK D: Construction of an adenovirus SV40 recom-binant producing SV40 T antigen from an adenovirus late promoter. Cell (1981) 24:135–143.
   PubMed Web of Science ®Google Scholar
• GLUZMAN Y, REICHL H, SOLNICK D: Helper-free ade-novirus type-5 vectors. In: Eukalyotic viral vectors. Gluzman Y (Ed.), Cold Spring Harbor Laboratory, New York, (1982)187–192.
   Google Scholar
• THUMMEL C, TJAN R, HU SH et al.: Translational control of SV40 T antigen expressed from the adenovirus late promoter. Cell (1983) 33:455–464.
   PubMed Web of Science ®Google Scholar
• YAMADA M, LEWIS JA, GRODZICKER T: Overproduction of the protein product of a nonselected foreign gene carried by an adenovirus vector. Proc. Natl. Acad. Sci. USA (1985) 82:3567–3571.
   PubMed Web of Science ®Google Scholar
• HUANG J, JACOBI G, HAJ-AIMAD Y et al: Expression of the HSV-2 ribonucleotide reductase subunits in ade-novirus vectors or stably transformed cells: restoration of enzymatic activity by reassociation of enzyme subunits in the absence of other HSV proteins. Virology (1988) 163:462–470.
   PubMed Web of Science ®Google Scholar
• MANSOUR SL, GRODZICKER T, TJAN R: An adenovirus vector system used to express polyoma virus tumor antigens. Proc. Natl. Acad. Sci. USA (1985) 82:1359–1363.
   PubMed Web of Science ®Google Scholar
• MASSIE B, GLUZMAN Y, HASSELL JA et al.: Construction of a helper -free recombinant adenovirus that expresses polyomavirus large T antigen. Mol Cell Biol. (1986) 6:2872–2883.
   PubMed Web of Science ®Google Scholar
• SCHAFFHAUSEN BS, BOCKUS BJ, BERKNER KL et al: Char-acterisation of middle T antigen expressed by using an adenovirus expression system. J. Vim]. (1987) 61:1221–1225.
   Web of Science ®Google Scholar
• MATHEWS MB: Control of translation in adenovirus-in-fected cells. Enzyme (1990) 44:250–264.
   PubMedGoogle Scholar
• MATHEWS MB, SHENK T: Adenovirus virus-associated RNA and translation control. J. Vim]. (1991) 65:5657–5662.
   Web of Science ®Google Scholar
• ELOIT M, ADAM M, GALLAIS I et al: High level of trans-gene expression in cell cultures and in the mouse by replication-incompetent adenoviruses harboring modified VAI genes. J. Vim]. (1997) 71:5375–5381.
   Web of Science ®Google Scholar
• HILLEMAN MR: Epidemiology of adenovirus respiratory infections in military recruit populations. Ann. NY Acad. Sci. (1957) 67:262.
   PubMed Web of Science ®Google Scholar
• VAN DER VEEN J, KOK G: Isolation and typing of ade-noviruses recovered from military recruits with acute respiratory disease in the Netherlands. Am. J. Hyg. (1957) 65:119.
   PubMedGoogle Scholar
• VAN DER VEEN J, OEI JG, ABARBANEL MFW: Patterns ofinfections with adenovirus types 4, 7, and 21 in military recruits during a 9 year survey. J. Hyg. (Comb.) (1969) 67:255.
   PubMedGoogle Scholar
• BERKNER KL: Expression of heterologous sequences in adenoviral vectors. Curr. Topics Nlicrobiol. Immun. (1992)158:39-66. A comprehensive review of Ad-mediated gene expression.
   Google Scholar
• BUESCHNER EL: Respiratory disease and the ade-noviruses. Med. Clin. New Am. (1967) 51:769–779.
   PubMed Web of Science ®Google Scholar
• CHANOCK RM, LUDWIG W, HUEBNER RJ et al.: Immuni-zation by selective infection with type 4 adenovirus grown in human diploid tissue culture. JAMA (1966) 196:445–452.
   PubMedGoogle Scholar
• TOP FH: Control of adenovirus acute respiratory disease •in US army trainees. Yale J. Biol. Med. (1975) 48:185-195. A well-cited report on early trials with live Ad in humans.
   Google Scholar
• GRAHAM FC: Transformation by and oncogenicity of Human adenoviruses. In: The Adenoldruses. Ginsberg HS (Ed.), Plenum Press, New York (1984):339–398.
   Google Scholar
• RUBIN BA, RORKE LB: Adenovirus vaccine. In: Vaccine. Plotkin SA, Mortimer EA, Jr., (Eds.), WB Saunders, Philadel-phia (1988) 492–512.
   Google Scholar
• FOX JP, BRANDT CD, WASSERMAN FE et al.: The virus watch program: a continuing surveillance of viral in-fections in metropolitan New York families. VI. Obser-vations of adenovirus infections: virus excretion patterns, antibody response, efficiency of surveillance, patterns of infections and relation to illness. Am. J. Epidemiol. (1969) 89:25–50.
   Google Scholar
• HUNG PP, MORIN JE, LUBECK MD et al.: Recombinantadenovirus as a vehicle for the HBV surface antigen or HIV envelope protein genes. In: Human Retro viruses, Cancer and AIDS Approaches to Prevention and Therapy Liss, New York (1988) 349–361.
   Google Scholar
• ALKHATIB G, BRIEDIS DJ: High-level eukaryotic in vivo expression of biologically active measles virus hemag-glutinin by using an adenovirus type 5 helper-free vector system. J. Vim]. (1988) 62:2718–2727.
   Web of Science ®Google Scholar
• JOHNSON DC, GHOSH-CHOUDHURY G, SMILEY JR et al: Abundant expression of herpes simplex virus glyco-protein gB using an adenovirus vector. Virology (1988) 164:1–14.
   PubMed Web of Science ®Google Scholar
• GRUNHAUS A, HORWITZ MS: Adenoviruses as cloning •vectors. Semin. Vim]. (1992) 3:237-252. A good review of recombinant Ad vectors.
   Google Scholar
• PARDOLL D: Cancer Vaccines. Trends Pharmacol. Sci. (1993) 14:202–208.
   Google Scholar
• FEARON ER et al.: Interleukin 2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60:397–403.
   PubMed Web of Science ®Google Scholar
• HENNEY CS, KURIBAYASKI K, KERN DE et al: Interleukin 2 augments natural killer cell activity. Nature (1981) 291:335–338.
   PubMed Web of Science ®Google Scholar
• LOTZE MT, GRIMM EA, MAZUMDER A et al: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. (1981) 41:4420–4425.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, SPIESS P, LAFRENIERE R: A new approach •to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 233:1318-1321. An introductoty report outlining the application of TIL for cancer therapy.
   Google Scholar
• PARKINSON DR: Interleukin 2 in cancer therapy. Semin. Oncol (1988) 15:10–26.
   PubMed Web of Science ®Google Scholar
• GANSBACHER B, ZIER K, CRONIN K et al: Retroviral gene transfer induced constitutive expression of inter-leukin2 or interferon-y in irradiated human melanoma cells. Blood (1992) 80:2817–2825.
   PubMed Web of Science ®Google Scholar
• HADDADA H, RAGOT T, CORDIER L et al.: Adenoviral •interleukin-2 gene transfer into p815 tumor cells abrogates turnorigenicity and induces antitumoral immunity in mice. Human Gene Ther. (1993) 4:703-711. An early experimental report on Ad-mediated IL-2 gene transfer in a cancer model.
   Google Scholar
• ADDISON CL, BRACIAK T, RALSTON R et al: Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Nati Acad. Sci. USA (1995) 92:8522–8526.
   PubMed Web of Science ®Google Scholar
• TOLOZA EM, HUNT K, SWISHER S et al.: In vivo cancer gene therapy with a recombinant interleukin-2 ade-novirus vector. Cancer Gene Ther. (1996) 3:11–17.
   PubMed Web of Science ®Google Scholar
• HUANG H, CHEN SH, KOSAI K et al.: Gene therapy for hepatocellular carcinoma: long-term remission of pri-mary and metastatic tumors in mice by interleukin-2 gene therapy in vivo. Gene Ther. (1996) 3:980–987.
   PubMed Web of Science ®Google Scholar
• BRAMSON JL, HITT M, GALLICHAN WS eta].: Construction •of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo produc-tion of biologically active interleukin-12. Human Gene Ther. (1996) 7:333-342. An experimental study on Ad-mediated IL-12 gene transfer in a mouse cancer model.
   Google Scholar
• BRAMSON JL, HITT M, ADDISON CL et al: Direct intratu-moral injection of an adenovirus expressing inter-leukin-12 induces regression and long-lasting immunity that is associated with highly localised ex-pression of interleukin-12. Human Gene Ther (1996) 7: 1995-2002.
   Google Scholar
• DESSUREAULT S, GRAHAM F, GALLINGER S: B7-1 gene transfer into human cancer cells by infection with an adenovirus-B7 (AdV-B7) expression vector. Ann. Surg Oncol. (1996) 3:317–324.
   PubMed Web of Science ®Google Scholar
• TRINCHIERI G: Interleukin 12: a cytokine produced by antigen-presenting cells with immunoregulatory func-tions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood (1994) 84:4008–4027.
   PubMed Web of Science ®Google Scholar
• FREEMAN GJ, FREEMAN AS, SEGIL JM et al.: B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol (1987) 143:2714–2722.
   Web of Science ®Google Scholar
• CHEN L, ASHE S, BRADY WA et al.: Costimulation of •antitumor immunity by the B7 counter-receptor for the lymphocyte molecules CD28 and CTLA-4. Cell (1992) 71:1093-1102. Study of co-stimulatory molecules.
   Google Scholar
• TOWNSEND SE, ALLISON JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected mela-noma cells. Science (1993) 259:368–370.
   PubMed Web of Science ®Google Scholar
• ZHAI Y, YANG JC, KAWAKAMI Y et al: Development and •characterisation of recombinant adenoviruses encod-ing MARTI or gp100 for cancer therapy. IITIM UT I. (1996) 156:700-710. A report of Ad-mediated tumour-specific antigen vaccines.
   Google Scholar
• SMITH RR, HUEBNER RJ, ROVVE WP et al.: Studies on the use of viruses in the treatment of carcinoma of thecervix. Cancer (1956) 9:1211-1218. An early trial of wild-type Ad in cancer therapy.
   Google Scholar
• DESCAMPS V, DUFFOUR MT, MATHIEU MC et al.:Strategies for cancer gene therapy using adenoviral vectors. J. Mol Med. (1996) 74:183–189.
   PubMed Web of Science ®Google Scholar
• ZHANG W-W, FANG X: Gene therapy strategies for can- •cer. Exp. Opin. Invest. Drugs (1995) 4:487-514. A comprehensive review on strategies for gene therapy for cancer.
   Google Scholar
• MONTENARH M: Biochemical, immunological, and •functional aspects of the growth-suppressor/oncopro-tein p53. Grit. Rev. Oncog (1992) 3:233-256. A thorough review of the biochemical, immunological, and func-tional aspects of p53.
   Google Scholar
• TOMINAGO O, HAMELIN R, REMVIKOS Y eta].: p53 from basic research to clinical applications. Crit. Rev. Oncog (1002) 3:257–282.
   Google Scholar
• BARTEK J, BARTKOVA J, VOJTESSEK B et al.: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene (1991) 6: 1699-1703.
   Google Scholar
• HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B et al.: p53 mutations in human cancers. Science (1991) 253:49–53.
   PubMed Web of Science ®Google Scholar
• BAKER SJ, MARKOWITZ S, FEARSON ER et al: Suppression • of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 249:912-915. First report of tumour suppressor activity of the wild-type p53 gene.
   Google Scholar
• CAI DW, MUKHOPADHYAY T, LIU Y et al: Stable expres-sion of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Human Gene Ther. (1993) 4:617–624.
   PubMed Web of Science ®Google Scholar
• ZHANG W-W, FANG X, BRANCH CD eta': Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. BioTechniques (1993) 15:868–872.
   PubMed Web of Science ®Google Scholar
• WANG J, BUCANA CD, ROTH JA et al.: Apoptos is induced in human osteosarcoma cells is one of the mechanisms for tumoricidal effect of Ad5CMV-p53. Cancer Gene Ther. (1995) 2:9–17.
   PubMed Web of Science ®Google Scholar
• LIU T-J, ZHANG W-W, TAYLOR DL eta': Growth suppres-sion of human head and neck cancer cells by the introduction of a wild-type p53 gene viaa recombinant adenovirus. Cancer Res. (1994) 54:3662–3667.
   PubMed Web of Science ®Google Scholar
• WILLS KN, MANEVAL DC, MENZEL P et al.: Development and characterisation of recombinant adenoviruses en-coding human p53 for gene therapy of cancer. Human Gene Ther. (1994) 5:1079–1088.
   PubMed Web of Science ®Google Scholar
• KAMB A, BRUIS NA, WEAVER-FELDHAUS J et al.: A cell •cycle regulator potentially involved in genesis of many tumor types. Science (1994) 264:436-440. First report of p16 and p15 as major tumour suppressors (MTS).
   Google Scholar
• JIN X, NGUYEN D, ZHANG W-W et al.: Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res. (1995) 55:3250–3253.
   PubMed Web of Science ®Google Scholar
• SANDIG V, BRAND K, HERWIG S et al.: Adenovirally transferred p1eK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med. (1997) 3:313–319.
   PubMed Web of Science ®Google Scholar
• LED WITH BJ, MANAM S, KRAYNAK AR et al.: Antisense-fos RNA causes partial reversion of the transformation phenotypes induced by the c-Ha-ras oncogene. Mol. Cell Biol. (1990) 10:1545–1555.
   PubMed Web of Science ®Google Scholar
• SKLAR MD, THOMPSON E, WELSH MJ et al: Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells. Mol Cell Biol. (1991) 11:3699–3710.
   PubMed Web of Science ®Google Scholar
• MUKHOPADHYAY T, TAINSKY M, CAVENDER AC et al.: Specific inhibition of K-ras expression and tu-morigenicity of lung cancer cells by antisense RNA. Cancer Res. (1991) 51:1744–1748.
   PubMed Web of Science ®Google Scholar
• ALEMANY R, RUAN S, KATOAKA M et al: Growth inhibi-tory effect of anit-K-ras adenovirus on lung cancer cells. Cancer Gene Ther. (1996) 3:296–301.
   PubMed Web of Science ®Google Scholar
• HUBER BE, RICHARDS CA, KRENITSKY TA: Retroviral-me-diated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA (1991) 88:8039–8043.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL: Tumor chemosensitivity conferred by •inserted herpes thymidine kinase genes: a paradigm for a prospective cancer control strategy. Cancer Res (1986) 46:5276-5281. An early report of the application of prodrug for cancer therapy.
   Google Scholar
• BORRELLI E, HEYMAN R, HSI M et al.: Targeting of an inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci. USA (1988) 85:7572–7576.
   PubMed Web of Science ®Google Scholar
• EZZEDDINE ZD, MARTUZA RL, PLATIKA D et al.: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymid-ine kinase gene. The New BioL (1991) 3:608–614.
   PubMedGoogle Scholar
• MULLEN CA, KILSTRUP ME, BLAESE RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA (1992) 89:33–37.
   Google Scholar
• HUBER BE, AUSTIN EA, GOOD SS et al: In vivo antitumor activity of 5-fluorocytosine on human colorectal carci-noma cells genetically modified to express cytosine deaminase. Cancer Res. (1993) 53:4619–4626.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL: Drug sensitivity ('suicide') genes for se-lective cancer chemotherapy. Cancer Gene Ther. (1994) 1:279–287.
   PubMed Web of Science ®Google Scholar
• CARVER RI, GOLDSMITH KT, RODU B et aL: Strategy for •achieving selective killing of carcinomas. Gene Ther. (1994) 1:46-50. A discussion of the selective killing of carcinomas.
   Google Scholar
• CHEN S-H, SHINE HD, GOODMAN JC et al: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Nall Acad. Sci. USA (1994) 91:3054–3057.
   PubMed Web of Science ®Google Scholar
• COLAK A, GOODMAN JC, CHEN S-H et al: Adenovirus-me-diated gene therapy in experimental model of breast cancer metastatic to the brain. Human Gene Ther. (1995) 6:1317–1322.
   PubMed Web of Science ®Google Scholar
• ANDERSEN L, KILSTRUP M, NEUHARD J: Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coil' K12. Involvement of the ginG and purR genes in the regulation of codA expres-sion. Arch. Microbiol. (1989) 152:115–118.
   Google Scholar
• AUSTIN EA, HUBER BE: A first step in development of gene therapy for colorectal carcinoma: cloning, se-quencing, and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol 43:380–387.
   Google Scholar
• HIRSCHOWITZ EA, OHWADA A, PASCAL WR et al: In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carci-noma-derived tumors induces chemosensitivity to 5-fluorocytosine. Human Gene Ther. (1995) 6:1055–1063.
   PubMed Web of Science ®Google Scholar
• HART I: Tissue specific promoters in targeting systemi- •cally delivered gene therapy. Semin. Oncol. (1996) 23:154-158. A good review outlining the tissue-specific promoter strategy for gene therapy.
   Google Scholar
• OSAKI,T, TANIO Y, TACHIBANA I et al Gene therapy for carcinoembryonic antigen-producing human lung can-cer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. (1994) 54:5258–5261.
   PubMed Web of Science ®Google Scholar
• RICHARDS CA, AUTSIN EA, HUBER BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Human Gene Ther. (1995) 6:881–893.
   PubMed Web of Science ®Google Scholar
• SMITH MJ, ROUSCULP MD, GOLDSMITH KT et al: Surfac-tant protein A-directed toxin gene kills lung cancer cells in vitro. Human Gene Ther. (1994) 5:29–35.
   PubMed Web of Science ®Google Scholar
• MANOME Y, ABE M, HAGEN MR et al.: Enhancer se-quences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to gancyclovir. Cancer Res. (1994) 54:5408–5413.
   PubMed Web of Science ®Google Scholar
• CHEN L, CHEN D, MANOME Y et al: Breast cancer selec-tive gene expression and therapy mediated by recom-binant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. (1995) 96:2775–2782.
   PubMed Web of Science ®Google Scholar
• IDO A, NAKATA K, KATO Y et al.: Gene therapy for hepatoma cells using a retrovirus vector carrying her-pes simplex virus thymidine kinase gene under the control of human -Fetoprotein gene promoter. Cancer Res. (1995) 55:3105–3109.
   PubMed Web of Science ®Google Scholar
• KANEKO S, HALLENBECK P, KOTANI T et al: Adenovirus-mediate gene therapy of hepatocellular carcinoma us-ing cancer-specific gene expression. Cancer Res. (1995) 55:5283–5287.
   PubMed Web of Science ®Google Scholar
• KANAI F, SHIRATORI Y, YOSHIDA et al: Gene therapy for fetoprotein-producing human hepatoma cells by ade-novirus -mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology (1996) 23:1359–1368.
   PubMed Web of Science ®Google Scholar
• VILE RG, HART IR: ht vitro and in vivo targeting of gene expression to melanoma cells. CancerRes. (1993) 53:963–967.
   Google Scholar
• SIDERS WM, HALLORAN PJ, FENTON RG: Transcriptional targeting of recombinant adenoviruses to human and mmine melanoma cells. Cancer Res. (1996) 56:5638–5646.
   PubMed Web of Science ®Google Scholar
• DEPACZ NG: Sulla acoparsa di un enorme cancro vege-tante del callo dell'utero senza cura chirurgica. Ginecolo-gia (1912) 9:82–88
   Google Scholar
• ROWE WP, HUEBNER R, GILMORE LK et al: Isolation of a cytopathogenic agent from human adenoids undergo-ing spontaneous degeneration in tissue culture. Proc. Soc. Exper. Biol. Med. (1953) 84:570–573.
   PubMed Web of Science ®Google Scholar
• RAO L, DEBBAS M, SABBATINI P et al.: The adenovirus ElA proteins induce apoptos is which is inhibited by the ElB 19K and Bc1-2 proteins. Proc. Natl. Acad. Sci. USA (1992) 89:7742–7746.
   PubMed Web of Science ®Google Scholar
• DEBBAS M, WHITE E: Wild-type p53 mediates apoptosis by ElA which is inhibited by ElB. Gene Dev. (1993) 7:546–554.
   PubMed Web of Science ®Google Scholar
• YU D, WOLF JK, SCANLON M et al.: Enhanced c-erbB-2/ neu expression in human ovarian cancer cells corre-lates with more severe malignancy that can be suppressed by ElA. Cancer Res. (1993) 53:891–898.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, YU D, XIA Wet al.: HER-2/neu-targeting cancer therapy via adenovirus-mediated ElA delivery in an animal model. Oncogene (1995) 10:2263–2270.
   Google Scholar
• CHANG JY, XIA W, SHAO R et al.: Inhibition of intratra-cheal lung cancer development by systemic delivery of ElA. Oncogene (1996) 13:1405–1412.
   PubMed Web of Science ®Google Scholar
• BARKER DD, BERK AJ: Adenovirus proteins from both ElB reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology (1987) 156:107–121.
   PubMed Web of Science ®Google Scholar
• BISCHOFF JR, KIRN DH, WILLIAMS A eta].: An adenovirus •mutant that replicates selectively in p53-deficient hu-man tumor cells. Science (1996) 274:373-376. A report of tumour-selective Ad-mediated oncolysis.
   Google Scholar
• HEISE C, SAMPSON-JOHANNES A, WILLIAMS A et al.: ONYX-015, an ElB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. (1997) 3:639–645.
   PubMed Web of Science ®Google Scholar
• HALLENBECK PL, CHANG YN, HAY C et al.: Novel tumor specific replication competent adenoviral vectors for gene therapy of cancer . Cancer Gene Ther. (1996) 3:S19–20.
   Google Scholar
• RODRIGUEZ R, SCHUUR ER, LIM HY eta].: Prostate attenu- •ated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559-2563. An experimental report on tumour-specific replicative Ad.
   Google Scholar
• ROSENFELD MA, SIEGRIED W, YOSHIMURA K et al.: Ade-novirus-mediated transfer of a recombinant 1-antitryp-sin gene to the lung epithelium in viva Science (1991) 252:431-434. A study of Ad-mediated gene therapy in Wyo.
   Google Scholar
• GOMEZ-FOIX AM, COATS WS, BAQUE S eta].: Adenovirus-mediated transfer of the muscle glycogen phosphory-lase gene into hepatocytes confers altered regulation of glycogen metabolism. J. Biol. Chem. (1992) 267:25129–25134.
   Google Scholar
• STRATFORD-PERRICAUDET L, MAKEH L, PERRICAUDET M et al.: Widespread long-term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. (1992) 90:626–630.
   PubMed Web of Science ®Google Scholar
• RICH DP, COUTURE M, CARDOZA LM eta].: Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Human Gene Ther. (1993) 4:461–476.
   PubMed Web of Science ®Google Scholar
• QUANTIN B, PERRICAUDET LD, TAJBAKHSH S eta]: Ade-novirus as an expression vector in muscle cells in viva Proc. Natl. Acad. Sci. USA (1992) 89:2581-2584. An study of Ad-mediated gene transfer via im. injection.
   Google Scholar
• HERZ J, GERARD RD: Adenovirus-mediated transfer of •low density lipoprotein receptor gene acutely acceler-ates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA (1993) 90:2812-2816. An early study of Ad-mediated gene transfer in vivo in mice.
   Google Scholar
• LE GAL LA SALLE G, ROBERT JJ, BERNARD S et al.: An adenovirus vector for gene transfer into neurons and glia in the brain. Science (1993) 259:988–990.
   Google Scholar
• MASHHOUR B, COUTON D, PERRICAUDET Metal.: In vivo adenovirus-mediated gene transfer into ocular tissues. Gene Ther. (1994) 1:122–126.
   Google Scholar
• HOLZINGER A, TRAPNELL BC, WEAVER TE et al.: Intraam-niotic administration of an adenoviral vector for gene transfer to fetal sheep and mouse tissues. Ped. Res. (1995) 38:844–850.
   PubMed Web of Science ®Google Scholar
• HUARD J, LOCHMULLER J, ACSADI G eta]: The route of administration is a major determinant of the transduc-tion efficiency of rat tissues by adenoviral recombi-nants. Gene Ther. (1995) 2:107–115.
   PubMed Web of Science ®Google Scholar
• COX DW: ai-antitryps in deficiency. In: The Metabolic and MolecularBases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.), McGraw-Hill, Inc. (1995):4125–4158.
   Google Scholar
• LEMARCHAND P, JAFFE HA, DANEL C et al: Adenovirus-mediated transfer of a recombinant human at-antitryp-sin cDNA to human endothelial cells. Proc. Natl. Acad. Sci. USA (1992) 89:6482–6486.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN JL, HOBBS HH, BROWN MS: Familial hyper-cholesterolemia. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.), McGraw-Hill, Inc. (1995) :1981–2030.
   Google Scholar
• KOZARSKY K, GROSSMAN M, WILSON JM: Adenovirus-mediated correction of the genetic defe ct in hepatocytes from patients with familial hypercholesterolemia. So-matic Cell Mol. Gen. (1993) 19:449–458.
   PubMed Web of Science ®Google Scholar
• KOZARSKY KF, MCKINLEYS DR, AUSTIN LL eta]: In vivo correction of low density lipoprotein receptor defi-ciency in the watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J. Biol. Chem. (1994) 269:1–8.
   PubMedGoogle Scholar
• LI J, FANG B, EISENSMITH RC, LI XHC eta]: In vivo gene therapy for hyperlipidemia: phenotypic correction in watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J. Clin. Invest. (1995) 95:768–773.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI K, OKA K, FORTE T eta]: Reversal of hyper-cholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J. Biol. Chem. (1996) 271:6852–6860.
   PubMed Web of Science ®Google Scholar
• GRUBB BR eta]: Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature (1994) 371:802–806.
   PubMed Web of Science ®Google Scholar
• ZABNER J, COUTURE LA, SMITH AE et al: Correction of cAMP-stimulated fluid secretion in cystic fibrosis air-way epithelia: efficiency of adenovirus-mediated gene transfer in vitro. Human Gene Ther. (1994) 5:585–593.
   PubMed Web of Science ®Google Scholar
• YEI S, MITTEREDER N, VVERT S et al.: In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Human Gene Ther. (1994) 5:733–746.
   Google Scholar
• ENGELHARDT JF, YANG Y, STRATFORD-PERRICAUDET LD eta]: Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with El-deleted ade-noviruses. Nature Gen. (1993) 4:27–34.
   PubMed Web of Science ®Google Scholar
• SIMON RH, ENGELHARDT JF, YANG Y et al.: Adenovirus- •mediated transfer of the CFTR gene to lung of nonhu-man primates: toxicity study. Human Gene Ther (1993) 4:771-780. An early study measuring the toxicity of Ad-mediated gene transfer.
   Google Scholar
• ROSENFELD MA, CHU C-S, SETH P eta].: Gene transfer to freshly isolated human respiratory epithelial cells in vitro using a replication deficient adenovirus contain-ing the human cystic fibrosis transmembrane conduc-tance regulator cDNA. Human Gene Ther. (1994) 5:331–342.
   Google Scholar
• MITTEREDER N, YEI SO, BACHURSKI C et al: Evaluation of the efficacy and safety of in vitro adenovirus-medi-ated transfer of the human cystic fibrosis transmem-brane conductance regulator cDNA. Human Gene Ther. (1994) 5:717–729.
   PubMed Web of Science ®Google Scholar
• GOLDMAN MJ, YANG Y, WILSON JM: Gene therapy in a xenograft model of cystic fibrosis lung corrects chlo-ride transport more effectively than the sodium defect. Nature Gen. (1995) 9:126–131.
   PubMed Web of Science ®Google Scholar
• ZABNER J, COUTURE LA, GREGORE RJ et al: Adenovirus-mediated gene transfer transiently corrects the chlo-ride transport defect in nasal epithelia of patients with cystic fibrosis. Cell (1993) 75:207–216.
   PubMed Web of Science ®Google Scholar
• CRYSTAL RG, MCELVANEY NG, ROSENFELD MA et al.:
   Google Scholar
• Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Gen. (1994) 8:42-51. First report of Ad-mediated CFTR gene therapy in clinical trials.
   Google Scholar
• GOLDMAN MJ, LITZKY LA, ENGELHARDT JF et al: Transfer of the CFTR gene to the lung of nonhuman primates with El-deleted, E2a-defective recombinant ade-noviruses: a preclinical toxicology study. Human Gene Ther. (1995) 6:839–851.
   PubMed Web of Science ®Google Scholar
• St GEORGE JA, PENNINGTON SE, KAPLAN JM et al.: Bio-logical response of nonhuman primates to long-term repeated lung exposure to AdV2/CFTR-2. Gene Ther. (1996) 3:103–116.
   PubMed Web of Science ®Google Scholar
• KAPLAN JM, St GEORGE JA, PENNINGTON SE et al.: Hu-moral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther. (1996) 3:117–127.
   PubMed Web of Science ®Google Scholar
• FISHER KJ, CHOI H, BURDA J et al.: Recombinant ade- •novirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology (1996) 217:11-22. An early report of Ad vectors with entire coding sequence deleted.
   Google Scholar
• KOENIG M, HOFFMAN EP, BERTELSON CJ et al: Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell (1987) 50:509–517.
   PubMed Web of Science ®Google Scholar
• WOLFF JA, MALONE R, WILLIAMS P et al.: Direct gene transfer into mouse muscle in vivo. Science (1990) 247:1465–1468.
   PubMed Web of Science ®Google Scholar
• ACSADI G, DICKSON G, LOVED et al: Human dystrophin expression in mdx mice after injection of DNA con-structs. Nature (1991) 352:815–818.
   PubMed Web of Science ®Google Scholar
• DUNCKLEY MG, LOVE DR, DAVIES KE et al.: Retroviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro. FEBS Lett. (1992) 296:128–134.
   PubMed Web of Science ®Google Scholar
• RAGOT T, VINCENT N, CHAFEY et al.: Efficient ade-novirus-mediated transfer of human minidystrophin gene to skeletal muscle of mcbc mice. Nature (1993) 361:647–650.
   PubMed Web of Science ®Google Scholar
• WELLS DJ, WELLS KE, WALSH FS et al: Human dystrophin expression corrects the myopathic phenotype in trans-genic mcbc mice. Human Mol Gen. (1992) 1:35–40.
   PubMed Web of Science ®Google Scholar
• COX GA, COLE NM, KATSUMARA K et al: Overexpression of dystrophin in transgenic mdx mice eliminates dys-trophic symptoms without toxicity. Nature (1993) 364:725–729.
   PubMed Web of Science ®Google Scholar
• HAUSER MS, PHELPS SF, CHAMBERLAIN JS: Expression of dystrophin minigenes in the muscles of mdx mice partially prevents the development of dystrophic symptoms. Am. J. Human Gen. (1994) 55:A47.
   Google Scholar
• VINCENT N, RABOT T, GILDENKRANTZ H et al: Long-term •correction of mouse dystrophic degeneration by ade-novirus-mediated transfer of a minidystrophin gene. Nature Gen. (1993) 5:130-134. An early study of Ad-mediated DMD minigene transfer.
   Google Scholar
• ACSADI G, LOCHMULLER H, JANI A et al.: Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Human Gene Ther. (1996) 7:129–140.
   PubMed Web of Science ®Google Scholar
• KOCHANEK S, CLEMENS PR, MITANI K et al.: A new adenoviral vector: replacement of all viral coding se-quences with 28 kB of DNA independently expressing both full-length dystrophin and P-galactosidase. Proc. Natl. Acad. Sci. USA (1996) 93:5731-5736. The first report on packaging-attenuated helper Ad.
   Google Scholar
• HAECKER SE, STEDMAN HH, BALICE-GORDON RJ et al: In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Human Gene Ther. (1996) 7:1907–1914.
   PubMed Web of Science ®Google Scholar
• SMITH T: Gene therapy for hemophilia. Exp. Opin. Invest.
   Google Scholar
• •Drugs (1995) 4:833-842. A comprehensive review on gene therapy for haemophilia
   Google Scholar
• PALMER TD, THOMPSON AR, MILLER Ad: Production of human Factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. Blood (1989) 73:438–445.
   PubMed Web of Science ®Google Scholar
• SCHARFMANN R, AXELROD JH, VERMA IM: Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc. Nail. Acad. Sci. USA (1991) 88:4626–4630.
   PubMed Web of Science ®Google Scholar
• YAO SN, WILSON JM, NABEL EG et al.: Expression of human Factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. Proc. Natl. Acad. Sci. USA (1991) 88:8101–8105.
   PubMed Web of Science ®Google Scholar
• DAI Y, ROMAN M, NAVIAUX RK et al: Gene therapy in primary myoblasts: long-term expression of Factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. USA (1992) 89:10892–10895.
   PubMed Web of Science ®Google Scholar
• GERRARD AJ, HUDSON DL, BROWNLEE GG et al: Towards gene therapy for hemophilia B using primary human kerstinocytes. Nature Gen. (1993) 3:180–183.
   PubMed Web of Science ®Google Scholar
• SMITH TAG, MEHAFFEY MG, KAYDA DB et al: Adenovirus mediated expression of therapeutic plasma levels of human Factor IX in mice. Nature Gen. (1993) 5:397–402.
   PubMed Web of Science ®Google Scholar
• DAI Y, SCHWARZ EM, GU D et al.: Cellular and hurnoral immune responses to adenoviral vectors containingFactor IX gene: tolerisation of Factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA (1995) 92:1401-1405. A study of Ad-mediated IX gene transfer in mice with well-controlled experiments on host immune response to Ad vectors.
   Google Scholar
• FANG B, EISENSMITH RC, WANG H et al.: Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated Factor IX expression. Human Gene Ther. (1995) 6:1039–1044.
   PubMed Web of Science ®Google Scholar
• KAUFMAN RJ: Biological regulation of Factor VIII activ- •ity. Ann. Rev. Med. (1992) 43:325-339. A comprehensive review of Factor VIII.
   Google Scholar
• HOYER LW: Hemophilia A. New Engl. J. Med. (1994) 330:38–47.
   PubMed Web of Science ®Google Scholar
• HOEBEN RC, VAN DER JAGT RC, SCHOUTE F et al: Expres-sion of functional Factor VIII in primary human skin fibroblasts after retrovirus-mediated gene transfer. J. Biol. Chem. (1990) 265:7318–7323.
   PubMed Web of Science ®Google Scholar
• LYNCH CM, ISRAEL DI, KAUFMAN RJ et al.: Sequences in the coding region of clotting Factor VIII act as dominant inhibitors of RNA accumulation and protein produc-tion. Human Gene Ther. (1993) 4:259–272.
   PubMed Web of Science ®Google Scholar
• DWARKI VJ, BELLONI P, NIJJAR T et al.: Gene therapy for hemophilia A: production of therapeutic levels of hu-man Factor VIII in vivo in mice. Proc. Natl. Acad. Sci. USA (1995) 92:1023–1027.
   PubMed Web of Science ®Google Scholar
• CONNELLY S, SMITH TAG, DHIR G et al.: In vivo gene •delivery and expression of physiological levels of func-tional human Factor VIII in mice. Human Gene Ther. (1995) 6:185-193. First report of high-level Factor VIII in vivo gene expression mediated by Ad vector.
   Google Scholar
• CONNELLY S, GARDNER JM, MCCLELLAND A et al: High-level tissue-specific expression of functional human Factor VIII in mice. Human Gene Ther. (1996) 7:183–195.
   PubMed Web of Science ®Google Scholar
• CONNELLY S, ANDREWS JL, GALLO AM et al.: Expression of human Factor VIII in hemophiliac mice and primary human hepatocytes. In: Molecular and Cellular Biology of Gene Therapy. Keystone Symposia, Silverthome, Colorado (1997) 46 (Abstract).
   Google Scholar
• ALEMANY R, DAI Y, LOU YC et al.: Complementation of •helper-dependent adenoviral vectors: size effects and titre fluctuations. J. Vim]. Method (1997). (In Press). An early experimental study on mini-Ad vector system and the first report on Factor VIII mini-Ad.
   Google Scholar
• SCRIVER CR et al.: MMBID-7 summary table. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.), McGraw-Hill, Inc. (1995):1–50.
   Google Scholar
• BRUSILOW SW, HORWICH AL: Urea cycle enzymes. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.), McGraw-Hill, Inc. (1995) : 1187–1231 .
   Google Scholar
• MORSY MA, ALFORD EL, BETT A et al.: Efficient adenovi-ral-mediated ornithine trans carbamylase expression in deficient mouse and human hepatocytes. J. Clin. Invest. (1993) 92:1580–1586.
   PubMed Web of Science ®Google Scholar
• SCRIVER CR, KAUFMAN S, EISENSMITH RC et al.: The hype rphenylalaninemias In: The Metabolic and Molecu-lar Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds.), McGraw-Hill, Inc. (1995):1015–1076.
   Google Scholar
• FANG B, EISENSMITH RC, LI XH et al.: Gene therapy for phenylketonuria: a phenotypic correction in a geneti-cally deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther. (1994) 1:247–254.
   PubMed Web of Science ®Google Scholar
• JONES N, SHENK T: Isolation of deletion and substitution mutants of adenovirus type 5. Cell (1978) 13:181–188.
   PubMed Web of Science ®Google Scholar
• GHOSH-CHOUDHURY G, HAJ-AHMAD Y, GRAHAM FL: Protein IX, a minor component of the human ade-novirus capsid, is essential for the packaging of full-length genomes. EMBO J (1987) 6:1733–1739.
   PubMed Web of Science ®Google Scholar
• AIELLO L, GUILFOYLE R, HUEBNER K et al.: Adenovirus 5 DNA sequences present and RNA sequences transcribed in transformed human embryo kidney cells (HEK-Ad-5 or 293). Virology (1979) 94:460–469.
   PubMed Web of Science ®Google Scholar
• SHENK T, JONES N, COLBY W et al.: Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harbor Symp. Quant Biol. (1979) 44:367–375.
   Google Scholar
• YANG Y, NUNES FA, BERENCSI K et al.: Cellular immunity •to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA (1994) 91:4407-4411. An early report of host cellular immunity that eliminates Ad-vector transduced cells.
   Google Scholar
• YEI S, MITTEREDER N, TANG K et al.: Adenovirus-medi- •ated gene transfer to cystic fibrosis: quantitative evalu-ation of repeated in vivo vector administration to the lung. Gene Ther. (1994) 1:192-200. Quantitative study of repeated in vivo vector administration to the lung.
   Google Scholar
• YANG Y, LI Q, ERTL HCJ et al.: Cellular and humoral immune response to viral antigens create barriers to lung-directed gene therapy with recombinant ade-noviruses. Vim]. (1995) 69:2004–2015.
   Google Scholar
• DONG JY, WANG D, VAN GINKEL FW et al.: Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Human Gene Ther. (1996) 7:319–331.
   Google Scholar
• WORGALL S, WOLFF G, FALCK-PEDERSEN E et al.: Innate immune mechanisms dominate elimination of ade-noviral vectors following in vivo administration. Hu-man Gene Ther. (1997) 8:37–44.
   PubMed Web of Science ®Google Scholar
• IMPERIALE MJ, KAO H-T, FELDMAN JR et al.: Common control of the heat shock gene and early adenovirus genes: evidence for a cellular E1A-like activity. Mol. Cell Biol. (1984) 4:867–874.
   PubMed Web of Science ®Google Scholar
• SPERGEL JM, HSU W, AKIRA S et al.: NF-116, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A.j Virol. (1992) 66:1021–1030.
   PubMed Web of Science ®Google Scholar
• JONES N, SHENK T: Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell (1979) 17:683–689.
   PubMed Web of Science ®Google Scholar
• YANG Y, NUNES FA, BERENCSIK eta': Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy for cystic fibrosis. Nature Gen. (1994) 7:362–369.
   PubMed Web of Science ®Google Scholar
• YANG Y, JOOS KU, SU Q et al: Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. (1996) 3:137–144.
   PubMed Web of Science ®Google Scholar
• SONG W, KONG H-L, TRAKTMAN P et al.: Cytotoxic T lymphocyte responses to proteins encoded by het-erologous transgenes transferred in vivo by adenoviral vectors. Human Gene Ther. (1997) 8:1207–1217.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT JF, LITZKY L, WILSON JM: Prolonged trans-gene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Human Gene Ther. (1994) 5:1217–1229.
   PubMed Web of Science ®Google Scholar
• WADSWORTH SC, ZHOU H, SMITH AE et al.: Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J. Vim]. (1997) 71:5189–5196.
   Web of Science ®Google Scholar
• MASTRANGELI A, HARVEY BG, YAO J et al: Sero-switch' •adenovirus-mediated in vivo gene transfer: circumven-tion of anti-adenovirus hurnoral immune defences against repeat adenovirus vector administration by changing the adenovirus serotype. Human Gene Ther. (1996) 7:79-87. An early study of the feasibility of avoiding host anti-Ad responses by switching the Ad serotype.
   Google Scholar
• MULLBACKER A, BELLETT AJ, HLA RT: The murine cellular immune response to adenovirus type 5. Immunot Cell Biol. (1989) 67:31–39.
   PubMed Web of Science ®Google Scholar
• ZINKERNAGEL RM: Immunity of viruses. In: Fundamental Immunology Paul WE (Ed.), Raven Press, New York (1993): 1211–1250.
   Google Scholar
• FALLAUX FJ, KRANENBURG O, CRAMER SJ et al: Charac- •terisation of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Human Gene Ther. (1996) 7:215-222. An early report outlining the construction of a new 293-like cell line.
   Google Scholar
• IMLER J-L, CHARTIER C, DREYER D et al: Novel comple- •mentation cell lines derived from human lung carci-noma A549 cells support the growth of El-deleted adenovirus vectors. Gene Ther. (1996) 3:75-84. An early report outlining the construction of a new 293-like cell line.
   Google Scholar
• TACKET CO, LOSONSKY G, LUBECK MD et al.: Initial safety and immunogenicity studies of an oral adeno-hepatitis B vaccine. Vaccine (1992) 10:673–676.
   PubMed Web of Science ®Google Scholar
• KLESSIG DF, BROUGH DE, CLEGHON V: Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell. Mot Cell Biol. (1984) 4:1354-1362. First report outlining the construction of an E2A-complementing cell line.
   Google Scholar
• RICE SA, KLESSIG DF: Isolation and analysis of ade-novirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. J. Vim]. (1985) 56:767–778.
   Web of Science ®Google Scholar
• BROUGH DE, CLEGHON V, KLESSIG DF: Construction, characterisation, and utilization of cell lines which inducibly express the adenovirus DNA-binding protein. Virology (1992) 190:624–634.
   PubMed Web of Science ®Google Scholar
• VVEINBERG DH, KETNER G: A cell line that supports the •growth of a defective early region 4 deletion mutant of human adenovirus type 2. Proc. Nail. Acad. Sci. USA (1983) 80:5383-5386. First report of an E4-complementing cell line.
   Google Scholar
• BRIDGE E, KETNER G: Redundant control of adenovirus late gene expression by early region 4. J. Virot (1989) 63:631–638.
   PubMed Web of Science ®Google Scholar
• GORZIGLIA MI, KADAN MJ, YEI S et al.: Elimination of •both El and E2a from adenovirus vectors further im-proves prospects for in vivo human gene therapy. J. Vim]. (1996) 70:4173-4178. An early report of El- and E2a-deleted cell lines and the correspond-ing vectors.
   Google Scholar
• ZHOU H, O'NEAL W, MORRAL N et al: Development of a complementing cell line and a system for construction of adenovirus vectors with El and E2a deleted. J. Vim]. (1996) 70:7030–7038.
   Web of Science ®Google Scholar
• MORRAL N, O'NEAL W, ZHOU H et al: Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Human Gene Ther. 8:1275-1286.
   Google Scholar
• SCHAACK J, GUO X, YEW-WAI HO et al: Adenovirus type •5 precursor terminal protein-expressing 293 and HeLa cell lines. J. Virol. (1995) 69:4079-4085. An early report on El- and E2b-complementing cell lines.
   Google Scholar
• AMALFITANO A, BEGY CR, CHAMBERLAIN JS: Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. USA (1996) 93:3352–3356.
   PubMed Web of Science ®Google Scholar
• AMALFITANO A, CHAMBERLAIN JS: Isolation and charac-terisation of packaging cell lines that coexpress the adenovirus El, DNA polymerase, and preterminal pro-teins: implications for gene therapy. Gene Ther. (1997) 4:258–263.
   PubMed Web of Science ®Google Scholar
• KROUGLIK V, GRAHAM FL: Development of cell lines •capable of complementing El, E4, and protein Di defec-tive adenovirus type 5 mutants. Human Gene Ther. (1995) 6:1575-1586. An early report of an El-, E4-complementing cell line.
   Google Scholar
• GAO GP, YANG Y, WILSON JM: Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy. J. Vim]. (1996) 70:8934–8943.
   Web of Science ®Google Scholar
• LIEBER A, HE CY, KIRILLOVA I et al.: Recombinant ade- •noviruses with large deletions generated by cre-medi-ated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Vim]. (1996) 70:8944-8960. An early study reporting the deletion of a large sequence of the Ad vector and comparing this to El-deleted Ad vector.
   Google Scholar
• DEUSCHLE U, MEYER WK-H, THIESEN H-J: Tetracycline-reversible silencing of eukaryotic promoters. Mot. Cell Biol. (1995) 15:1907–1914.
   Web of Science ®Google Scholar
• ENGELHARDT JF, YE X, DORANZ B et al.: Ablation of E2A •in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. (1994) 91:6196-6200. An early study outlining the improvement of the El-substituted Ad vector system.
   Google Scholar
• FANG B, WANG H, GORDON G et al: Lack of persistence of El- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompe-tent mice and hemophilia B dogs. Gene Ther. (1996) 3:217–222.
   PubMed Web of Science ®Google Scholar
• STERNBERG N, HAMILTON D: Bacteriophage P1 site-spe-cific recombination. L Recombination between loxP sites. J. Mol. Biol. (1981) 150:467–486.
   PubMed Web of Science ®Google Scholar
• SAUER B: Site-specific recombination: developments and applications. Curr. Opin. Biotech. (1994) 5:521–527.
   PubMedGoogle Scholar
• ARMENTANO D, SOOKDEO CC, HEHIR KM et al: Charac- •terisation of an adenovirus gene transfer vector con-taining an E4 deletion. Human Gene Ther. (1995) 6:1343-1353. An early report of El- and E4-deleted Ad vectors.
   Google Scholar
• ARMENTANO D, ZABNER J, SACKS C et al: Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virof (1997) 71:2408–2416.
   PubMed Web of Science ®Google Scholar
• LOCHMULLER H, PETROF BJ, ALLEN C et al: Immunosup-pression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic (mdx) mice. Biochem. Biophys. Res. Commun. (1995) 213:569–574.
   PubMed Web of Science ®Google Scholar
• KAPLAN JM, SMITH AE: Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to re-administer adenoviral vec-tor to the mouse lung. Human Gene Ther. (1997) 8:1095–1104.
   PubMed Web of Science ®Google Scholar
• YANG Y, TRINCHIERI G, WILSON JM: Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. (1995) 1:890–893.
   PubMed Web of Science ®Google Scholar
• YANG Y, SU Q, IQBAL S et al.: Transient subversion of •CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Vim]. (1996) 70:6370-6377. A report outlining the blockade of anti-Ad responses.
   Google Scholar
• GUERETTE B, VILQUIN JT, GINGRAS M et al: Prevention of immune reactions triggered by first-generation ade-noviral vectors by monoclonal antibodies and CTLA4Ig. Human Gene Ther. (1996) 7:1455–1463.
   PubMed Web of Science ®Google Scholar
• YANG Y, GREENOUGH K, WILSON JM: Transient immune blockade prevents formation of neutralising antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. (1996) 3:412–420.
   PubMed Web of Science ®Google Scholar
• DEMATTEO RP, MARKMANN JF, KOZARSKY KF et al.:
   Google Scholar
• •Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. Gene Ther. (1996) 3:4-12 An experimental report of the use of T-cell depletion for the suppression of anti-Ad responses.
   Google Scholar
• MORRIS SC et al: Effects of 11-12 on in vivo cytokine gene expression and Ig isotype selection. J. Immunol (1994) 152:1047–1056.
   PubMed Web of Science ®Google Scholar
• POSSELT AM, BARKER CF, TOMASZEWSKI JF et al: Induc- •tion of donor-specific unresponsiveness by in-trathymic islet transplantation. Science (1990) 249:1293-1295. An early study of central tolerisation.
   Google Scholar
• OLUWOLE SF, JIN MX, CHOWDHURY NC et al.: Induction of peripheral tolerance by intrathymic inoculation of soluble alloantigens: evidence for the role of host antigen presenting cells and suppressor cell mecha-nism. Cell Immunol (1995) 162:33–41.
   PubMed Web of Science ®Google Scholar
• DEMATTEO RP, RAPER SE, AHN M et al.: Gene transfer to the thymus: a means to abrogate the immune response to recombinant adenovirus. Ann. Surg. (1995) 222:229–242.
   PubMed Web of Science ®Google Scholar
• ILAN Y, ATTAVAR P, TAKAHASHI M et al.: Induction of central tolerance by intrathymic inoculation of ade-noviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J. Clin. Invest. (1996) 98:2640–2647.
   PubMed Web of Science ®Google Scholar
• DEMATTEO RP, CHU G, AHN M et al.: Long-lasting ade- •novirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppre ssion. .1 Vim]: (1997) 71:5330-5335. An experimental report of neonatal intrathymic tolerance induction.
   Google Scholar
• KASS-EISLER A, LEINWAND L, GALL J et al: Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. (1996) 3:154–162.
   PubMed Web of Science ®Google Scholar
• HIERHOLZER JC: Adenoviruses in the immunocom-promised host. Clin. Microbiol. Rev. (1992) 5:262–274.
   PubMed Web of Science ®Google Scholar
• SCHNURR D, DONDERO ME: Two new candidate ade-novirus serotypes. Intervirology (1993) 36:79–83.
   PubMed Web of Science ®Google Scholar
• SHENK T: Adenoviridae: the viruses and their replica-tion. In: Fields Virology. Fields BN, Knipe DM, Howley PM (Eds.), Lippincott-Raven, Philadelphia (1996):2111.
   Google Scholar
• MACK CA, SONG W-R, CARPENTER H et al Circumvention of anti-adenovirus neutralising immunity by administration of an adenoviral vector of an alternate sero-type. Human Gene Ther. (1997) 8:99–109.
   PubMed Web of Science ®Google Scholar
• KAIER B, WIGAND R: Antigenic homogeneity of ade-novirus types 1, 2, 5, and 6.J. Med. Virof (1986) 18:283–287.
   PubMed Web of Science ®Google Scholar
• ADAM E, NASZ I, LENGYEL A: Antigenic homogeneity among the adenovirus hexone types of subgenus C. Arch. Virol (1995) 140:1297–1301.
   PubMed Web of Science ®Google Scholar
• ROBINSON AJ, YOUNGHUSBAND BH, BELLETT AJD: A circular DNA protein complex from adenovirus. Virol-ogy (1973) 56:54.
   PubMed Web of Science ®Google Scholar
• CHALLBURG MD, OSTROVE J, KELLY TJ, Jr.: Initiation of adenovirus DNA replication: detection of covalent com-plexes between nucleotide and the 80-kd terminal pro-tein. J. Virol (1982) 41:365.
   Google Scholar
• CASJENS S: Nucleic acid packaging by viruses. In: Virus Structure and Assembly. Casjens S (Ed.), Jones and Bartlett Publishers, Boston (1985):75–147.
   Google Scholar
• REISS M, FISHER RA, SIEGELE DA eta].: Packaging of the bacteriophage lambda chromosome: a role for the base sequences outside. Virology (1979) 92:56.
   Google Scholar
• LEVRERO M, BARBAN V, MANTECA S et al: Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo. Gene (1991) 101:195–202.
   PubMed Web of Science ®Google Scholar
• YOUNG CSH, SHENK T, GINSBERG: The genetic system. In: The Adenoviruses. Ginsberg HS (Ed.), Plenum Publishing Corp., New York (1984) 125–172.
   Google Scholar
• GLUZMAN Y, VAN DOREN K: Palindromic adenovirus •type 5-simian virus 40 hybrid. J. Virol. (1983) 45:91-103. An experimental report of naturally occurring substitution of the Ad genome with foreign DNA.
   Google Scholar
• DEURING R, KLOTZ G, DOERFLER W: An unusual sym- •metric recombinant between adenovirus type 12 DNA and human cell DNA. Proc. Natl. Acad. Sci. USA (1981) 78:3142-3146. An experimental report of naturally occurring substitution of the Ad genome with foreign DNA.
   Google Scholar
• BREDENBEEK PJ, FROLOV I, RICE CM et al.: Sindbis virus •expression vectors: packaging of RNA relicons by using defective helper RNAs. j Vim]. (1993) 67:6439-6446. An example of a packaging-attenuated helper.
   Google Scholar
• MITANI K, GRAHAM F, CASKEY CT et al: Rescue, propa-gation, and partial purification of a helper virus-de-pendent adenovirus vector. Proc. Natl. Acad. Sci. USA (1995) 92:3854–3858.
   PubMed Web of Science ®Google Scholar
• KUMARY-SINGH R, CHAMBERLAIN JS: Encapsidated ade-novirus minichromosomes allow delivery and expres-sion of a 14 kb dystrophin cDNA to muscle cells. Human Mot. Gen. (1996) 5:913–921.
   PubMed Web of Science ®Google Scholar
• ALEMANY R, DAI Y, LOU Y-C et al: Complementation of adenoviral vectors with a helper virus partially deleted in the packaging signal. In: Abstracts of Papers Presented at the 1996 Meeting on Gene Therapy Cold Spring Harbor, New York (1996):18.
   Google Scholar
• PARKS RJ, CHEN L, ANTON M et al.: A helper-dependent adenovirus vector system: removal of helper virus by cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA (1996) 93:13565-13570. The first report of selective packaging deletion of helper Ad.
   Google Scholar
• PARKS RJ, GRAHAM FL: A helper-dependent system for •adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol. (1997) 71:3293-3298. An experimental study of packaging size limit for Ad vectors.
   Google Scholar
• CLEMENS PR, KOCHANEK S, SUNADA Y et al.: In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. (1996) 3:965–972.
   PubMed Web of Science ®Google Scholar
• CHEN HH, MACK LM, KELLY R et al: Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. USA (1997) 94:1645–1650.
   PubMed Web of Science ®Google Scholar
• MICHAEL S, HONG J, CURIEL D et al.: Addition of a short •peptide ligand to the adenovirus fibre protein. Gen. Ther. (1995) 2:660-669. An early experimental report of fibre modification for Ad targeting.
   Google Scholar
• WICKHAM TJ, SEGAL DM, ROELVINK PW et al.: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol (1996) 70:6831–6838.
   PubMed Web of Science ®Google Scholar
• KRASNYKY VN, MIKHEEVA GV, DOUGLAS JT eta!: Gen-eration of recombinant adenovirus vectors with modi-fied fibres for altering viral tropism. J. Virol. (1996) 70:6839–6846.
   PubMed Web of Science ®Google Scholar
• DOUGLAS JT, ROBERS BE, ROSENFELD ME eta!: Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotech. (1996) 14:1574–1577.
   PubMed Web of Science ®Google Scholar
• WICKHAM TJ, ROELVINK PW, BROUGH DE et al.: Ade-novirus targeted to heparan-containing receptors in-creases its gene delivery efficiency to multiple cell types. Nature Biotech (1996) 14:1570–1573.
   PubMed Web of Science ®Google Scholar
• FENDER P, RUIGROK RWH, GOUT E et al.: Adenovirus •dodecahedron, a new vector for human gene transfer. Nature Biotech. (1997) 15:52-56. An report of artificial Ad vectors.
   Google Scholar
• STEWART PL, BURNETT RM, CYRKLAFF M et al.: Image reconstruction reveals the complex molecular organi-zation of adenovirus. Cell (1991) 67:145–154.
   PubMed Web of Science ®Google Scholar
• WOHLGEMUTH JG, RANG SH, BULBOACA GH eta!: Long-term gene expression from autonomously replicating vectors in mammalian cells. Gene Ther. (1996) 3:503–512.
   PubMed Web of Science ®Google Scholar
• BALAGUE C, KALLA M, ZHANG W-W: Adeno-associated •Rep78 protein and terminal repeats enhance integra-tion of DNA sequences into the cellular genome.J. Virol (1997) 71:3299-3306. An experimental study of AAV/ITR-rep mediated integration.
   Google Scholar
• BILBAO G, FENG M, RANCOURT C et al.: Adenovi- •ral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J (1997) 11:624-634. An interesting Ad/retroviral chimeric vector.
   Google Scholar
• GOLDSMITH KT, CURIEL DT, ENGLER JA et al.: Trans complementation of an E1A-deleted adenovirus with codelivered ElA sequences to make recombinant ade-noviral producer cells. Human Gene Ther. (1994) 5:1341–1348.
   PubMed Web of Science ®Google Scholar